Is depression an inflammatory condition? A review of available evidence

Journal of the Pakistan Medical Association

Volumn 63, Issue 7, 2013, Pages 899-906

  Hashmi, Ali Madeeh ^a   Butt, Zeeshan ^a   Umair, Muhammad ^a  

^a KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Cytokines; Depression; Inflammation

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CYTOKINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE STRESS; BLOOD BRAIN BARRIER; CORTICOSTEROID BLOOD LEVEL; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; META ANALYSIS (TOPIC); MICROGLIA; MOOD DISORDER; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SUICIDAL IDEATION;

ANIMALS; CYTOKINES; DEPRESSION; HUMANS; INFLAMMATION;

EID: 84879289247     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders IV. Washington, DC:American Psychiatric Publishing, Inc; 1994.
2. Kessler RC, Angermeyer M, Anthony JC, de Graaf R, Demyttenaere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007; 6:168-176.
3. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the global burden of disease study. Science 1996; 274:740-3.
4. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-105.
5. Dodani S, Zuberi RW. Center-based prevalence of anxiety and depression in women of the northern areas of Pakistan. J Pak Med Assoc 2000; 50:138-40.
6. Rasheed S, Khan MA, Khan B, Khan MY. Depression in medical in-patients. Pak Armed Forces Med J 2003; 53:132-5.
7. Shah S, Hassan SS, Ahmed M, Shah H, Ali R. Anxiety and depression in patients and controls. J Rawal Med Coll 2006; 10:86-9.
8. Kocsis JH, Klein DN (eds.). Diagnosis and Treatment of Chronic Depression. New York: Guilford Press; 1995.
9. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of theagency for health care policy and research practice guidelines. Arch Gen Psychiatry 1998; 55:1121-7.
10. Akiskal HS, Akiskal K. Cyclothymic, hyperthymic and depressive temperaments as subaffective variants of mood disorders. In: Tasman A, Riba MB, (eds.). Annual Review of Psychiatry. Vol. 11. Washington, DC: American Psychiatric Press; 1992.
11. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007; 9:449-59.
12. Adler DA, McLaughlin TJ, Rogers WH, Chang H, Lapitsky L, Lerner D. Job performance deficits due to depression. Am J Psychiatry 2006; 163:1569-76.
13. Lerner D, Adler DA, Chang H, Berndt ER, Irish JT, Lapitsky L, et al. The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med 2004; 46 (suppl 6): S46-55.
14. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160:3278-85.
15. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5:157-68.
16. Murphy JM, Horton NJ, Monson RR, Laird NM, Sobol AM, Leighton AH. Cigarette smoking in relation to depression: historical trends from the Stirling County Study. Am J Psychiatry 2003; 160:1663-9.
17. van Gool CH, Kempen GI, Penninx BW, Deeg DJ, Beekman AT, van Eijk JT. Relationship between changes in depressive symptoms and unhealthy lifestyles in late middle aged and older persons: results from the Longitudinal Aging Study Amsterdam. Age Ageing 2003; 32:81-7.
18. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62:792-8.
19. Patten SB, Williams JV, Lavorato DH, Modgill G, Jette N, Eliasziw M. Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. Gen Hosp Psychiatry 2008; 30:407-13.
20. Seguin M, Lesage A, Chawky N, Guy A, Daigle F, Girard G, et al. Suicide cases in New Brunswick from April 2002 to May 2003: the importance of better recognizing substance and mood disorder comorbidity. Can J Psychiatry 2006; 51:581-6.
21. US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US preventive services task force recommendation statement. Pediatrics 2009;123:1223-8.
22. Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. J Child Psychol Psychiatry 2006; 47:372-94.
23. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130:226-38.
24. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000; 886:172-89.
25. Dhabhar FS. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann N Y Acad Sci 2000; 917:876-93.
26. Griffiths J, Ravindran AV, Merali Z, Anisman H. Dysthymia: a review of pharmacological and behavioral factors. Mol Psychiatry 2000; 5:242-61.
27. Wheeler RD, Owens T. The changing face of cytokines in the brain: perspectives from EAE. Curr Pharm Des 2005; 11:1031-7.
28. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 2002; 8:RA165-77.
29. Cotter RL, Burke WJ, Thomas VS, Potter JF, Zheng J, Gendelman HE. Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. J Leukoc Biol 1999; 65:416-27.
30. Goehler LE, Erisir A, Gaykema R P. Neural-immune interface in the rat area postrema. Neuroscience 2006; 140:1415-34.
31. Roitt I, Brostoff J, Male D. Immunology. 4th ed. London: Mosby; 1996.
32. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2009;22:32-6.
33. Cunningham ET Jr., De Souza EB. Interleukin 1 receptors in the brain and endocrine tissues. Immunol Today 1993; 14:171-6.
34. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2001; 26:761-88.
35. Hayley S, Mangano E, Strickland M, Anisman H. Lipopolysaccharide and a social stressor influence behaviour, corticosterone and cytokine levels: divergent actions in cyclooxygenase-2 deficient mice and wild type controls. J Neuroimmunol 2008; 197:29-36.
36. Buttini M, Boddeke H. Peripheral lipopolysaccharide stimulation induces interleukin-1 beta messenger RNA in rat brain microglial cells. Neuroscience 1995; 65:523-30.
37. Anisman H, Gibb J, Hayley S. Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology (Berl) 2008; 199:231-44.
38. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9:46-56.
39. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110:135-370.
40. Beyer CE, Boikess S, Luo B, Dawson LA. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 2002; 16:297-304.
41. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004; 29:566-79.
42. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004; 7:193-218.
43. White KJ, Walline CC, Barker EL. Serotonin transporters: implications for antidepressant drug development. AAPS J 2005; 7:E421-33.
44. Laux G, Volz H, Müller H. Newer and older monoamine oxidase inhibitors. A comparative profile. CNS drugs 1995; 3:145-58.
45. Lopez-Munoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J Clin Psychopharmacol 2007; 27:555-9.
46. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 1986; 43:1155-61.
47. Dickinson S. Alpha2-adrenoceptor antagonism and depression. Drug News Perspect 1990;4:197-203.
48. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000; 12:1079-95.
49. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry 2002; 7(suppl 1):S23-8.
50. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr., Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 55:296-300.
51. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003; 64:1065-74.
52. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
53. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455:894-902.
54. Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry 2007; 68(suppl 8):4-10.
55. Sloman L. A new comprehensive evolutionary model of depression and anxiety. J Affect Disord 2008; 106:219-28.
56. Nesse RM. Is depression an adaptation? Arch Gen Psychiatry 2000; 57:14-20.
57. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002; 16:569-74.
58. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012;62:419-26.
59. Bah TM, Benderdour M, Kaloustian S, Karam R, Rousseau G, Godbout R. Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav Brain Res 2011; 225:243-51.
60. Castanon N, Bluthé RM, Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 2001;154:50-60.
61. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001;24:531-44.
62. Kubera M, Kenis G, Bosmans E, Scharpé S, Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 2000;23:89-98.
63. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 2010;62:683-93.
64. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011;61:592-9.
65. Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1306-16.
66. Masi G, Brovedani P. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 2011; 25:913-31.
67. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452-9.
68. Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun 2011;25:256-9.
69. Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009;42:182-8.
70. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012; 141:308-14.
71. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607-11.
72. Karaoulanis SE, Angelopoulos NV. The role of immune system in depression. Psychiatrike 2010;21:17-30.
73. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009;1179:86-105.
74. Antonioli M, Rybka J, Carvalho LA. Neuroimmune endocrine effects of antidepressants. Neuropsychiatr Dis Treat 2012;8:65-83.
75. Song JH, Marszalec W, Kai L, Yeh JZ, Narahashi T. Antidepressants inhibit proton currents and tumor necrosis factor-alpha production in BV2 microglial cells. Brain Res 2012;1435:15-23.
76. Wang Y, Cui XL, Liu YF, Gao F, Wei D, Li XW, et al. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Prog Neuropsychopharmacol Biol Psychiatry 201;35:1831-1835.
77. Chiou SH, Chen SJ, Peng CH, Chang YL, Ku HH, Hsu WM, et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 2006;343:391-400.
78. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011;60:963-974.
79. Kovaru H, Pav M, Kovaru F, Raboch J, Fiserova A. Cell signalling in CNS and immune system in depression and during antidepressant treatment: focus on glial and natural killer cells. Neuro Endocrinol Lett 2009;30:421-428.